Torl Biotherapeutics, Llc
Clinical trials sponsored by Torl Biotherapeutics, Llc, explained in plain language.
-
New drug combo aims to shrink ovarian tumors before surgery
Disease control Recruiting nowThis study tests whether adding the experimental drug TORL-1-23 to standard chemotherapy before surgery can improve outcomes for women with advanced ovarian cancer. About 60 participants with stage III or IV disease will receive the combination, then undergo surgery to remove rem…
Phase: PHASE1, PHASE2 • Sponsor: TORL Biotherapeutics, LLC • Aim: Disease control
Last updated May 17, 2026 00:47 UTC
-
New drug TORL-1-23 enters first human trial for advanced cancers
Disease control Recruiting nowThis early-stage study tests a new drug called TORL-1-23 in people with advanced solid tumors, including ovarian, endometrial, and lung cancers. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. About 90 participants will take part.
Phase: PHASE1 • Sponsor: TORL Biotherapeutics, LLC • Aim: Disease control
Last updated May 13, 2026 15:59 UTC
-
New hope for hard-to-treat ovarian cancer: targeted drug enters phase 2 trial
Disease control Recruiting nowThis study tests a drug called TORL-1-23 in 230 women with advanced ovarian, fallopian tube, or peritoneal cancer that no longer responds to platinum chemotherapy and has a specific marker (claudin 6). The goal is to see if the drug can shrink tumors and how safe it is. Participa…
Phase: PHASE2 • Sponsor: TORL Biotherapeutics, LLC • Aim: Disease control
Last updated May 11, 2026 20:38 UTC